FDA Policy/General

Workshop on Evidentiary Standards for Safety Biomarkers

Federal Register Notice: FDA and the Foundation for the National Institutes of Health Biomarkers Consortium (FNIH BC) will hold a public workshop 4/14-15 entitled “Developing an Evidentiary Standards Framework for Safety Biomarkers Qualification Workshop.” Its purpose is to discuss the evidentiary standards needed to support biomarker qualification with a particular emphasis on drug safety markers. The workshop will focus on the standards relevant to the qualification of a range of safety biomarkers and examine case studies in several different organ systems. It will be held 4/14 from 9 a.m. to 5 p.m. and 4/15, from 8 a.m. to 5 p.m. at the Bethesda North Marriott Hotel and Conference Center, 5701 Marinelli Rd., Bethesda, MD. Contact Janelle Lewis, (301) 594-2919. To view this notice, click here.

Gupta Raises Concerns About Overton’s Independence, Ideology

FDA commissioner nominee Heidi Overton’s responses on vaccines, contraception and abortion medication during her 9/24 Senate confirmation hearing raise concerns that ideology could influence her decision-making if she takes over the agency, MSNBC senior medical analyst Dr. Vin Gupta said Friday. Gupta was particularly critical of Overton’

Overton Confirmation Remains Uncertain After Senate Hearing

FDA commissioner nominee Heidi Overton emerged from her Senate confirmation hearing Thursday (see earlier story) without resolving questions about whether she has enough Republican support to advance — and with a rapidly narrowing window for confirmation before the midterm elections. The Senate Health, Education, Labor and Pensions Committee hearing provided few

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA has classified Boston Scientific's recall of its Imager II Angiographic Catheters as Class I because a manufacturing problem could cause catheter tips to degrade and detach, potentially resulting in life-threatening complications. The agency announced the Class I classification 9/25, updating an Early Alert it issued

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome

FDA has approved Roche’s Gazyva (obinutuzumab) for reducing the risk of relapse in adults and children aged 2 and older with frequently relapsing or steroid-dependent, childhood-onset idiopathic nephrotic syndrome who are in remission. The expanded approval covers the use of the CD20-directed antibody beyond its existing

Read more

Gupta Raises Concerns About Overton’s Independence, Ideology

Overton Confirmation Remains Uncertain After Senate Hearing

FDA Classifies Boston Scientific Imager II Catheter Recall as Class I

FDA Approves Gazyva for Childhood-Onset Idiopathic Nephrotic Syndrome